Skip to Content

Are you based in North America? If yes, switch to our North American website →

RET Breakapart

Applications
pathology
Catalogue Numbers
LPS 045 (10 tests)
LPS 045-S (5 tests)

The RET (ret proto-oncogene) gene at 10q11 encodes for a transmembrane tyrosine kinase receptor involved in the control of cell differentiation, cell proliferation, and cell survival1.

Rearrangements involving the RET gene are recognised recurrent abnormalities seen in 1-2% patients with lung adenocarcinomas, where it is seen fused with KIF5B2,3, and papillary thyroid carcinoma where it is seen fused to a number of different partner genes including: CCDC6, PRKAR1A and NCOA44,5. The features of the proteins encoded by all types of RET fusion gene are similar to those of ALK: coiled-coil domains in the N-terminal fusion partners cause the RET domains to dimerize, resulting in activation of RET tyrosine kinase in the absence of ligands3.

It was very important for us to have more consistent results with our probes — easy-to-read bright signals and a range of vial sizes, which is much more cost-effective. It also was critical to upgrade our pretreatment kit to expedite the analysis of FFPE samples. We can now complete the process in about 90 minutes. Janet M. Cowan, PhD, Director of the Cytogenetics Laboratory at Tufts Medical Center

References

1. Asai N, et al. Mol Cell Biol. 1995;15(3):1613–9

2. Kohno T et al., Nat Med 2012;18(3):375-7

3. Ju YS et al., Genome Res 2012;22(3):436-45

4. Colato C, et al., Eur J Endocrinol. 2015;172(5):571–82

5. Romei C et al., Front Endocrinol 2012;3:54

Microscope Images

RET Breakapart magnified
Area of Interest*
Lung Cancer

Disclaimer

This product is intended to be used on formalin-fixed paraffin-embedded (FFPE) tissues.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.